不對(duì)稱(chēng)催化氫化反應(yīng)是合成手性分子的重要方法之一，而C2對(duì)稱(chēng)性配體選擇是設(shè)計(jì)此類(lèi)反應(yīng)的關(guān)鍵。
DuPHOSTM是一種新穎的富電子C2對(duì)稱(chēng)性手性雙膦雜環(huán)戊烷配體，具有合適的立體位阻效應(yīng)。相對(duì)于其他類(lèi)型的手性雙膦配體，美國(guó)STREM工廠(chǎng)研發(fā)生產(chǎn)的DuPHOSTM和BPE配體，在烯酰胺、2-烷基琥珀酸、羥基酯、開(kāi)鏈烯醇酯、酮等類(lèi)型底物的不對(duì)稱(chēng)催化氫化反應(yīng)中顯示出了極高的對(duì)映體選擇性，因此被廣泛應(yīng)用于精細(xì)化工和醫(yī)藥行業(yè)中。
2008 年，百靈威與國(guó)際知名品牌STREM 正式簽署戰(zhàn)略合作協(xié)議，全權(quán)負(fù)責(zé)STREM 在中國(guó)市場(chǎng)的產(chǎn)品銷(xiāo)售、技術(shù)應(yīng)用與支持等各項(xiàng)業(yè)務(wù)。百靈威始終秉承“資源共享，共同發(fā)展”之理念，一如既往地為中國(guó)化學(xué)行業(yè)廣大科研和生產(chǎn)用戶(hù)提供品質(zhì)卓越的化學(xué)相關(guān)產(chǎn)品及服務(wù)，為實(shí)現(xiàn)“促進(jìn)科技與工業(yè)發(fā)展，造福人類(lèi)”的使命而不懈努力！
Sold in collaboration with Chirotech for research purposes only.1
Versatility of the DuPhos and BPE Ligand Systems in Asymmetric Catalytic Hydrogenation
1. For reviews see:- (a) M.J. Burk, Acc. Chem. Res. 2000, 33, 363. (b) I.C. Lennon, C.J. Pilkington, Synthesis, 2003, 1639.
2. M.J. Burk, J.E. Feaster, W.A. Nugent, R.L. Harlow, J. Am. Chem. Soc., 1993, 115, 10125.
3. M.J. Burk, J.G. Allen, W.F. Kiesman, J. Am. Chem. Soc., 1998, 120, 657.
4. A. Robinson, H.-Y. Li, J.E. Feaster, Tetrahedron Lett. 1996, 37, 8321.
5. M.J. Burk, J.R. Lee, Y. Wang, J. Am. Chem. Soc., 1996, 118, 5142.
6. a) M..J. Burk, G. Casy, N.B. Johnson, J. Org. Chem. 1998, 63, 6084.
b) P. Harrison, G. Meek, Tetrahedron Lett., 2004, 45, 9277.
7. E.A. Broger, Y. Crameri, R. Schmid, T. Siegrfried, Hoffman-La Roche, EP 0691 325 A, 1996.
8. M.J. Burk, F. Bienewald, M. Harris, A. Zanotti-Gerosa, Angew. Chem. Int. Ed. Engl, 1998, 37, 1931.
9. C.J. Cobley, I.C. Lennon, C. Praquin, A. Zanotti-Gerosa, R.B. Appell, C.T. Goralski, A.C. Sutterer, Org. Process Res. Dev.
2003, 7, 407.
10. M.J. Burk, F. Bienewald, S. Challenger, A. Derrick, J.A. Ramsden, J. Org. Chem. 1999, 64, 3290.
11. M.J. Burk, P.D. de Koning, T.M. Grote, M.S. Hoekstra, G. Hoge, R.A. Jennings, W.S. Kissel, T.V. Le, I.C. Lennon, T.A.
Mulhern, J.A. Ramsden,R.A. Wade, J. Org. Chem. 2003, 68, 5731.
12. N.W. Boaz, Tetrahedron Lett., 1998, 39, 5505.
13. M.J. Burk, C.S. Kalberg, A. Pizzano, J. Am. Chem. Soc., 1998, 120, 4345.
14. M.J. Burk, N.B. Johnson, J. Lee, Tetrahedron Lett. 1999, 40, 6685.
15. a) M.J. Burk, M.F. Gross, J.P. Martinez, J. Am. Chem. Soc. 1995, 117, 9375.
b) G.J. Roff, R.C. Lloyd, N.J. Turner, J. Am. Chem. Soc. 2004, 126, 4098.
16. M.E.B. Smith, M.C. Lloyd, N. Derrien, R.C. Lloyd, S.J.C. Taylor, D.A. Chaplin, G. Casy, R. McCague, Tetrahedron: Asymme
try 2001, 12, 703.
17. H-J. Drexler, J. You, S. Zhang, C. Fischer, W. Baumann, A. Spannenberg, D. Heller, Org. Process Res. Dev. 2003, 7, 355.
Phosphorus
|
|
(-)-1,2-Bis((2R,5R)-2,5-diethylphospholano)benzene,98+% (R,R)-Et-DUPHOS
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-diethylphospholano)benzene, 98+%(S,S)-Et-DUPHOS
|
100mg
500mg
2g
|
|
|
(+)-1,2-Bis((2R,5R)-2,5-diethylphospholano)ethane, 98+%(R,R)-Et-BPE
|
100mg
500mg
|
|
(-)-1,2-Bis((2S,5S)-2,5-diethylphospholano)ethane,98+%(S,S)-Et-BPE
|
100mg
500mg
|
|
|
(-)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)benzene,98+%(R,R)-Me-DUPHOS
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)benzene,98+% (S,S)-Me-DUPHOS
|
100mg
500mg
2g
|
|
|
(+)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)ethane,98+%(R,R)-Me-BPE
|
100mg
500mg
2g
|
|
(-)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)ethane, 98+% (S,S)-Me-BPE
|
100mg
500mg
2g
|
|
|
(+)-1,2-Bis((2R,5R)-2,5-di-i-propylphospholano)benzene,98+%(R,R)-i-Pr-DUPHOS
|
100mg
500mg
2g
|
|
(-)-1,2-Bis((2S,5S)-2,5-di-i-propylphospholano)benzene,98+% (S,S)-i-Pr-DUPHOS
|
100mg
500mg
2g
|
|
|
(-)-1,2-Bis((2R,5R)-2,5-diphenylphospholano)ethane, min.98%(R,R)-Ph-BPE
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-diphenylphospholano)ethane,min.98%(S,S)-Ph-BPE
|
100mg
500mg
2g
|
Rhodium
|
|
(R,R)-Duphos and BPE Rhodium Catalyst Kit Components availabe for individual sale.Contains 100mg of the following 7 items:
|
1kit
|
|
(S,S)-Duphos and BPE Rhodium Catalyst Kit Components availabe for individual sale.Contains 100mg of the following 7 items:
|
1kit
|
|
|
(-)-1,2-Bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate,98+%(R,R)-Et-DUPHOS-Rh
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate,98+% (S,S)-Et-DUPHOS-Rh
|
100mg
500mg
2g
|
|
|
(-)-1,2-Bis((2R,5R)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(R,R)-Et-DUPHOS-Rh
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(S,S)-Et-DUPHOS-Rh
|
100mg
500mg
2g
|
|
|
(-)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate, 98+% (R,R)-Me-DUPHOS-Rh
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) tetrafluoroborate,98+%(S,S)-Me-DUPHOS-Rh
|
100mg
500mg
2g
|
|
|
(-)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(R,R)-Me-DUPHOS-Rh
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)benzene(cyclooctadiene)rhodium(I) trifluoromethanesulfonate, 98+%(S,S)-Me-DUPHOS-Rh
|
100mg
500mg
2g
|
|
|
(+)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)ethane(cyclooctadiene)rhodium(I) tetrafluoroborate, 98+% (R,R)-Me-BPE-Rh
|
100mg
500mg
2g
|
|
(-)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)ethane(cyclooctadiene)rhodium(I) tetrafluoroborate,98+%(S,S)-Me-BPE-Rh
|
100mg
500mg
2g
|
|
|
(-)-1,2-Bis((2R,5R)-2,5-diphenylphospholano)thane(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(R,R)-Ph-BPE-Rh
|
100mg
500mg
2g
|
|
(+)-1,2-Bis((2S,5S)-2,5-diphenylphospholano)ethane(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(S,S)-Ph-BPE-Rh
|
100mg
500mg
2g
|
|
|
(+)-1,2-Bis((2R,5R)-2,5-di-i-propylphospholano)benzene(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(R,R)-i-Pr-DUPHOS-Rh
|
100mg
500mg
2g
|
|
(-)-1,2-Bis((2S,5S)-2,5-di-i-propylphospholano)benzene91,5-cyclooctadiene)rhodium(I) tetrafluoroborate,min.98%(S,S)-i-Pr-DUPHOS-Rh
|
100mg
500mg
2g
|
Exclusive world-wide license from DuPont for commercial applications in pharmaceuticals granted to Chirotech.
Research quantities available from Strem.
All items available for individual sale.